Hologic has been awarded a $119 million US govrnmen contract for the expansion of its production capacity for Covid-19 molecular tests. The contract will support investments that will enable Hologic to deliver 13 million Covid-19 tests each month in the US by January 2022.
DNAFit, a subsidiary of Hong Kong-based Prenetics Limited, has acquired Oxsed, an Oxford University spinout which has developed the RaVID Direct Covid-19 test kit. Th kit has a 92% to 100% sensitivity, providing a scalable and low-cost option for Covid-19 testing that can be carried out anywhere and provide results within 15-30 minutes. DNAFit and Prenetics now have exclusive global rights to Oxsed technologies.
Credo Diagnostics has received a CE mark for its VitaPCR™ Influenza A&B/SARS-CoV-2 assay, a rapid molecular test that helps in detecting Covid-19, flu A and flu B infections from a single sample. The three-in-one test across Credo Diagnostics VitaPCR™ systems worldwide and delivers results within 20 minutes.
Celltrion USA, a subsidiary of Korean medtech firm Celltrion, has signed a contract to supply $22m worth of Covid-19 diagnostic tests to the US. The contract was signed following the issuing of Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for Celltrion’s SAMPINUT rapid antigen test kit. The kits will be distributed with exclusive rights in New York.